HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Clinical study of the month. Nephroprotective role of angiotensin II receptor antagonists in type 2 diabetes: results of the IDNT and RENAAL trials].

Abstract
Nephropathy associated with type 2 diabetes mellitus is a rising cause of end-stage renal disease and is a major public health problem. If blocking of the renin angiotensin system has a well established nephroprotective effect in type 1 diabetic nephropathy, this remained to be shown for type 2 diabetes. Two large outcome trials using angiotensin II receptor antagonists (ARA's) in proteinuric chronic renal impairment and hypertensive type 2 diabetic patients have now closed this gap: the Irbesartan Diabetic Nephropathy Trial (IDNT) and the Reduction of Endpoints in NIDDM with Angiotensin II Antagonist Losartan (RENAAL) trial. Both trials showed a significant reduction in the primary pre-specified end-point of death, or worsening of renal function (doubling of serum creatinine) or the development of end-stage renal disease. This effect goes beyond the reduction in blood pressure and makes of ARA's one of the important tools in the treatment of type 2 diabetic nephropathy.
AuthorsL Weekers, J M Krzesinski
JournalRevue medicale de Liege (Rev Med Liege) Vol. 56 Issue 10 Pg. 723-6 (Oct 2001) ISSN: 0370-629X [Print] Belgium
Vernacular TitleEtude clinique du mois. Rôle néphroprotecteur des antagonistes du récepteur de l'angiotensine II (ARA) dans le diabète de type 2: résultats des études IDNT et RENAAL.
PMID11765585 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Angiotensin Receptor Antagonists
  • Antihypertensive Agents
  • Creatinine
Topics
  • Angiotensin Receptor Antagonists
  • Antihypertensive Agents (pharmacology)
  • Creatinine (metabolism)
  • Diabetic Nephropathies (complications, prevention & control)
  • Humans
  • Hypertension, Renal (complications)
  • Kidney Failure, Chronic (prevention & control)
  • Randomized Controlled Trials as Topic
  • Renin-Angiotensin System (drug effects, physiology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: